Back to Results

CorMedix Inc (CRMD)

Featured in High-Growth Small-Cap Stocks

CorMedix Inc. is a NASDAQ-listed healthcare company focused on biopharmaceutical development and commercialization for serious medical conditions in the United States. The company’s lead product candidate is DefenCath, an antimicrobial catheter lock solution designed to help reduce catheter-related bloodstream infections in adult patients with kidney failure. Founded in 2006 and based in Parsippany, New Jersey, CorMedix changed its name from Picton Holding Company, Inc. in January 2007. The company’s common stock trades on the NASDAQ under the symbol CRMD.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-CRMD
$9.09
16.8% Upside
Fair
$15.40
97.9% Upside
Bargain
Excellent
0.0%
November 11, 2026
3.3x
1.3x
1.3x
606.4 M
497.2 M
19.6%
84.5%
3.5
134.6%
Valuation • Fair Value

CorMedix Inc (NASDAQ-CRMD) Fair Value by Valuation Model

Review the available estimates for CorMedix Inc (NASDAQ-CRMD), including DCF Fair Value, Ben Graham Formula Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$9.09

Estimated upside of 16.8% versus the current market price.

Fair Value Confidence

Med

Confidence level for the primary fair value estimate.

DCF Fair Value

$11.59

Discounted cash flow valuation reference.

Ben Graham Formula Value

$26.48

Classic Ben Graham valuation formula reference.

Comps Fair Value

$8.67

Comparable-company valuation reference.

Analyst Price Target

$15.40

Analysts imply upside of 97.9%.

How to read these valuation models

Use the 6 available valuation references for CorMedix Inc (NASDAQ-CRMD) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for CorMedix Inc (NASDAQ-CRMD)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

462.2 M

Current operating scale indicator.

Revenue Forecast

335.4 M

Forward revenue estimate.

EBITDA

262.5 M

Current operating profitability reference.

EBITDA Forecast

127.3 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review CorMedix Inc (NASDAQ-CRMD) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for CorMedix Inc (NASDAQ-CRMD)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Excellent

Positive financial-health read.

Piotroski Score

4

Mid-range quality score.

Beneish M-Score

17.51

Higher caution zone on this screen.

Altman Z-Score

3.5

Relatively strong balance-sheet zone.

FCF / Net Income

134.6%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for CorMedix Inc (NASDAQ-CRMD). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for CorMedix Inc (NASDAQ-CRMD)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 11, 2026

Days to Earnings

50

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for CorMedix Inc (NASDAQ-CRMD), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

CorMedix Inc (NASDAQ-CRMD) Stock Forecast & Technical Outlook

Review CorMedix Inc (NASDAQ-CRMD) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for CorMedix Inc (NASDAQ-CRMD) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Neutral

The 1-hour technical read for CorMedix Inc (NASDAQ-CRMD) is currently Neutral. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for CorMedix Inc (NASDAQ-CRMD) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for CorMedix Inc (NASDAQ-CRMD) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Sell

The monthly technical read for CorMedix Inc (NASDAQ-CRMD) is currently Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for CorMedix Inc (NASDAQ-CRMD)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, CorMedix Inc (NASDAQ-CRMD) has a Strong Buy consensus, with 2 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 2
Hold 0
Sell 0
FAQ • Fast Investor Answers

CorMedix Inc (NASDAQ-CRMD) Stock FAQ

Data-supported answers about CorMedix Inc (NASDAQ-CRMD), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$9.09
Estimated upside 16.8%
Valuation Rating
Undervalued
Estimated upside of 16.8%
Analyst Target
$15.40
Implied upside 97.9%
Financial Health
Excellent
Current financial-health read

The current fair value estimate for CorMedix Inc (NASDAQ-CRMD) is $9.09. This implies an estimated upside of 16.8% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 16.8% versus the current market price.

The available analyst price target for CorMedix Inc (NASDAQ-CRMD) is $15.40. The analyst target implies estimated upside of 97.9%.

The current financial health read for CorMedix Inc (NASDAQ-CRMD) is Excellent. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for CorMedix Inc (NASDAQ-CRMD) is November 11, 2026.

The latest available data indicates no current dividend yield for CorMedix Inc (NASDAQ-CRMD).

The current P/E ratio listed for CorMedix Inc (NASDAQ-CRMD) is 3.3x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for CorMedix Inc is 606.4 M.

The current enterprise value listed for CorMedix Inc is 497.2 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for CorMedix Inc is NASDAQ-CRMD, and the stock is listed on NASDAQ.

CorMedix Inc (NASDAQ-CRMD) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for CorMedix Inc is 19.6%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for CorMedix Inc is 84.5%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

LLY NYSE Eli Lilly and Company Fair Value Fair Market Cap 1,043 B
JNJ NYSE Johnson & Johnson Fair Value Fair Market Cap 648.7 B
MRK NYSE Merck & Company Inc Fair Value Fair Market Cap 372.3 B
NVS NYSE Novartis AG ADR Fair Value Fair Market Cap 269.8 B
NVO NYSE Novo Nordisk A/S Fair Value Bargain Market Cap 175.3 B
PFE NYSE Pfizer Inc Fair Value Fair Market Cap 159.2 B
BMY NYSE Bristol-Myers Squibb Company Fair Value Fair Market Cap 127.2 B
SNY NASDAQ Sanofi ADR Fair Value Undervalued Market Cap 102 B
GSK NYSE GSK plc DRC Fair Value Undervalued Market Cap 101.9 B
TAK NYSE Takeda Pharmaceutical Co Ltd ADR Fair Value Fair Market Cap 60.536 B
TEVA NYSE Teva Pharma Industries Ltd ADR Fair Value Fair Market Cap 46.053 B
HLN NYSE HALEON PLC ADR Fair Value Fair Market Cap 40.268 B
RPRX NASDAQ Royalty Pharma Plc Fair Value Fair Market Cap 33.639 B
ZTS NYSE Zoetis Inc Fair Value Bargain Market Cap 30.107 B
VTRS NASDAQ Viatris Inc Fair Value Undervalued Market Cap 19.733 B
JAZZ NASDAQ Jazz Pharmaceuticals PLC Fair Value Fair Market Cap 15.616 B
CORT NASDAQ Corcept Therapeutics Incorporated Fair Value Overvalued Market Cap 12.702 B
ELAN NYSE Elanco Animal Health Fair Value Fair Market Cap 11.456 B
AXSM NASDAQ Axsome Therapeutics Inc Fair Value Fair Market Cap 10.639 B
RDY NYSE Dr. Reddy’s Laboratories Ltd ADR Fair Value Fair Market Cap 10.564 B